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ABSTRACT 
Breast cancer remains a complex disease that kills 40,000 women every year. Initiation 
and progression of breast cancer is influenced by heterogeneous groups of cells, including 
mammary cancer stem cells (MCSCs). Progression of this dreadful disease is driven by many 
signaling pathways among which MAPK pathway is highly prominent. Since targeting 
prominent kinases in MAPK pathway has been unsuccessful to control breast cancer, it is 
important to examine the phosphatases that regulate the activity of these kinases.   
Using xenograft model from breast cancer cell lines, our lab has found that during the 
initial stages of xenograft development (week 1-4, 100-200mg weight), ERK1/2 remains 
inactive. However, during the later stages of tumor development (week 5-15, 300-700mg 
weight), we found phospho-ERK1/2, which is the active form of ERK1/2 remains highly up 
regulated.  Our lab has also found that presence of inactive ERK1/2 during the initial stages of 
tumor development was independent of pMEK1/2, which is the upstream kinase that activates 
ERK1/2. We have also found that a specific dual specific phosphatase (DUSP9) was induced in 
the xenografts from breast cancer cell lines during initial stages of their development.  
I will be examining the significance of DUSP9 induction in the early stages of xenograft 
development.  There are reports that DUSP9-mediated pERK1/2 inactivation has been found to 
increase mouse embryonic stem cell content. I have been examining the expression levels of 
MCSCS (Aldehyde dehydrogenase 1(ALDH1)/ OCT3/4 / CD44/SOX2) in various stages of 
xenograft development and correlating them with DUSP9 expression and pERK1/2. I am 
examining the expression levels of MCSCs by Western blot analysis as well as qPCR. I have 
also been treating breast cancer cell line HMLEHRASV12 with MEK inhibitors, in vitro, for 
inactivating ERK to analyze the levels of mammary cancer stem cells (ALDH1)/ OCT3/4 / 
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CD44/SOX2. I am also examining the levels of DUSP9 as well as the levels of ERK/pERK1/2 
/AKT /pAKT in cells treated with MEK1/2 inhibitors in vitro. I intend to determine whether 
inhibition of pERK1/2 could influence embryonic stem cell content as analyzed by the 
expression of markers Oct ¾ and Sox2.  
 
Keywords:  Breast Cancer, Mammary Cancer Stem Cells, Xenograft 
 
ACKNOWLEDGEMENTS 
The STEP-UP HS program is supported by the National Institute of Diabetes and 
Digestive and Kidney Diseases of the National Institutes of Health, Grant Number:  
5R25DK078384-09. 
 
 
